LY2452473

LY2452473 is an orally bioavailable selective androgen receptor modulator (SARM) developed as a non-steroidal indole derivative. It acts as an agonist of the androgen receptor in select tissues such as skeletal muscle, bone, and the penis—promoting anabolic effects like increased muscle mass and strength—while acting as an antagonist in the prostate to block androgen receptor activation and inhibit cellular proliferation. This tissue-selective activity aims to provide therapeutic benefits for conditions like hypogonadism, erectile dysfunction, benign prostatic hyperplasia symptoms, and supportive care in prostate cancer without stimulating prostate growth. The drug was originally developed by Eli Lilly and later investigated by OPKO Health[1][2][5].

Other names

Isopropyl (2S)-7-Cyano-4-(pyridin-2-ylmethyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-2-ylcarbamate